Dexcom Stock

Dexcom Market capitalization

The The market capitalization of Dexcom (DXCM) as of Aug 8, 2026 is 26.95 B USD. In the previous year, The market capitalization was 26.95 B USD — a change of 0.00% (lower).

Market capitalization

26.95 BUSD

YoY

0.00%

Last updated:

In 2026, Dexcom's market cap stood at 26.95 B USD, a 0.00% increase from the 26.95 B USD market cap in the previous year.

The Dexcom Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Capitalization (undefined USD)
Date
Market Capitalization (undefined USD)
Jan 1, 2023
0.00 base
Jan 1, 2024
0.00 base
Jan 1, 2025
0.00 base
Jan 1, 2026 (e)
0.00 base
Jan 1, 2027 (e)
0.00 base
Jan 1, 2028 (e)
0.00 base
Jan 1, 2029 (e)
0.00 base
Jan 1, 2030 (e)
0.00 base
YEARMarket Capitalization (undefined USD)
2030 est -
2029 est -
2028 est -
2027 est -
2026 est -
2025 -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

Dexcom Stock analysis

What does Dexcom do? Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Dexcom's Market Capitalization

Dexcom's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Dexcom's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Dexcom's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Dexcom’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Dexcom stock

The market capitalization of Dexcom is 26.95 B USD in 2026.

The market capitalization of Dexcom changed from 26.95 B USD to 26.95 B USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Dexcom since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Dexcom with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Dexcom

All Key Metrics — Dexcom